The effect of losartan on differential reflex control of sympathetic nerve activity in chronic kidney disease

Journal of Hypertension

Volumn 33, Issue 6, 2015, Pages 1249-1260

  Yao, Yimin ^a   Hildreth, Cara M ^a   Farnham, Melissa M ^a,b   Saha, Manash ^a   Sun, Qi Jian ^a   Pilowsky, Paul M ^b   Phillips, Jacqueline K ^a  

^a MACQUARIE UNIVERSITY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

angiotensin II; baroreflex; chemoreflex; chronic kidney disease; somatosensory reflex; sympathetic nerve activity

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; LOSARTAN; NITROPRUSSIDE SODIUM; PHENYLEPHRINE; URETHAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL CHEMOREFLEX; CHEMORECEPTOR REFLEX; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; HYPERCAPNIA; KIDNEY NERVE; LATENT PERIOD; MALE; MEAN ARTERIAL PRESSURE; NERVE CONDUCTION; NERVE STIMULATION; NONHUMAN; PERIPHERAL CHEMOREFLEX; PRESSORECEPTOR; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SCIATIC NERVE STIMULATION; SOMATOSENSORY REFLEX; SOMATOSENSORY STIMULATION; SPINAL NERVE; SPLANCHNIC NERVE; SYMPATHETIC NERVE; SYMPATHETIC NERVE ACTIVITY; SYSTOLIC BLOOD PRESSURE; ADRENERGIC SYSTEM; ANIMAL; AUTONOMIC NERVE; DRUG EFFECTS; INNERVATION; KIDNEY; LEWIS RAT; LUMBOSACRAL REGION; METABOLISM; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AUTONOMIC PATHWAYS; BAROREFLEX; KIDNEY; LOSARTAN; LUMBOSACRAL REGION; MALE; NITROPRUSSIDE; PHENYLEPHRINE; RATS; RATS, INBRED LEW; RECEPTOR, ANGIOTENSIN, TYPE 1; RENAL INSUFFICIENCY, CHRONIC; SYMPATHETIC NERVOUS SYSTEM;

EID: 84929492517     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000535     Document Type: Article

References (52)

1. Tinucci T, Abrahao SB, Santello JL, Mion D Jr. Mild chronic renal insufficiency induces sympathetic overactivity. J Hum Hypertens 2001; 15:401-406.
2. Lacy P, Carr SJ, O'Brien D, Fentum B, Williams B, Paul SK, et al. Reduced glomerular filtration rate in predialysis nondiabetic chronic kidney disease patients is associated with impaired baroreceptor sensitivity and reduced vascular compliance. Clin Sci (Lond) 2006; 110:101-108.
3. Hering D, Zdrojewski Z, Krol E, Kara T, Kucharska W, Somers VK, et al. Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure. J Hypertens 2007; 25:157-161.
4. Converse RL, Jacobsen TN, Toto RD, Jost CMT, Cosentino F, Tarazi F, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912-1918.
5. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106:1974-1979.
6. Kotanko P. Cause and consequences of sympathetic hyperactivity in chronic kidney disease. Blood Purif 2006; 24:95-99.
7. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14:3239-3244.
8. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12:2427-2433.
9. Osborn JW, Kuroki MT. Sympathetic signatures of cardiovascular disease: a blueprint for development of targeted sympathetic ablation therapies. Hypertension 2012; 59:545-547.
10. Park J, Campese VM, Nobakht N, Middlekauff HR. Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease. J Appl Physiol 2008; 105:1873-1876.
11. Head GA, Saigusa T, Mayorov DN. Angiotensin and baroreflex control of the circulation. Braz J Med Biol Res 2002; 35:1047-1059.
12. Allen AM. Role of angiotensin in the rostral ventrolateral medulla in the development and maintenance of hypertension. Curr Opin Pharmacol 2011; 11:117-123.
13. Miyajima E, Shigemasa T, Yamada Y, Tochikubo O, Ishii M. Angiotensin II blunts, while an angiotensin-converting enzyme inhibitor augments, reflex sympathetic inhibition in humans. Clin Exp Pharmacol Physiol 1999; 26:797-802.
14. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Pozzi M, Morganti A, et al. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997; 96:1173-1179.
15. Neumann J, Ligtenberg G, Klein IHT, Boer P, Oey PL, Koomans HA, et al. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension 2007; 49:506-510.
16. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14:425-430.
17. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340:1321-1328.
18. McCooke JK, Appels R, Barrero RA, Ding A, Ozimek-Kulik JE, Bellgard MI, et al. A novel mutation causing nephronophthisis in the Lewis polycystic kidney rat localises to a conserved RCC1 domain in Nek8. BMC Genomics 2012; 13:393.
19. Salman IM, Hildreth CM, Ameer OZ, Phillips JK. Differential contribution of afferent and central pathways to the development of baroreflex dysfunction in chronic kidney disease. Hypertension 2014; 63:804-810.
20. Harrison JL, Hildreth CM, Callahan SM, Goodchild AK, Phillips JK. Cardiovascular autonomic dysfunction in a novel rodent model of polycystic kidney disease. Auton Neurosci Basic Clin 2010; 152:60-66.
21. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77:75-197.
22. Hottenrott C, Seufert R, Doertenbach J, Buckberg G. The influence of autonomous nervous activity on total and regional gastric blood flow. Scand J Gastroenterol Suppl 1984; 89:37-39.
23. Peyronnard JM, Charron LF, Lavoie J, Messier JP. Motor, sympathetic and sensory innervation of rat skeletal muscles. Brain Res 1986; 373:288-302.
24. Shahid IZ, Rahman AA, Pilowsky PM. Intrathecal orexin A increases sympathetic outflow and respiratory drive, enhances baroreflex sensitivity and blocks the somato-sympathetic reflex. Br J Pharmacol 2011; 162:961-973.
25. Abbott SB, Pilowsky PM. Galanin microinjection into rostral ventrolateral medulla of the rat is hypotensive and attenuates sympathetic chemoreflex. Am J Physiol Regul Integr Comp Physiol 2009; 296:R1019-R1026.
26. Egwuenu EJ, Fong AY, Pilowsky PM. Intrathecal melanin-concentrating hormone reduces sympathetic tone and blocks cardiovascular reflexes. Am J Physiol Regul Integr Comp Physiol 2012; 303:R624-R632.
27. Makeham JM, Goodchild AK, Costin NS, Pilowsky PM. Hypercapnia selectively attenuates the somato-sympathetic reflex. Respir Physiol Neurobiol 2004; 140:133-143.
28. Kimura A, Sato A, Sato Y, Suzuki H. A-and C-reflexes elicited in cardiac sympathetic nerves by single shock to a somatic afferent nerve include spinal and supraspinal components in anesthetized rats. Neurosci Res 1996; 25:91-96.
29. Nosaka S, Sato A, Shimada F. Somatosplanchnic reflex discharges in rats. J Auton Nerv Syst 1980; 2:95-104.
30. Burke PG, Neale J, Korim WS, McMullan S, Goodchild AK. Patterning of somatosympathetic reflexes reveals nonuniform organization of presympathetic drive from C1 and non-C1 RVLM neurons. Am J Physiol Regul Integr Comp Physiol 2011; 301:R1112-R1122.
31. Polson JW, Dampney RA, Boscan P, Pickering AE, Paton JF. Differential baroreflex control of sympathetic drive by angiotensin II in the nucleus tractus solitarii. Am J Physiol Regul Integr Comp Physiol 2007; 293:R1954-R1960.
32. Tan PS, Killinger S, Horiuchi J, Dampney RA. Baroreceptor reflex modulation by circulating angiotensin II is mediated by AT1 receptors in the nucleus tractus solitarius. Am J Physiol Regul Integr Comp Physiol 2007; 293:R2267-R2278.
33. Abdulla MH, Johns EJ. Nitric oxide impacts on angiotensin AT2 receptor modulation of high-pressure baroreflex control of renal sympathetic nerve activity in anaesthetized rats. Acta Physiol (Oxf) 2014; 210:832-844.
34. DiBona GF, Jones SY, Brooks VL. ANG II receptor blockade and arterial baroreflex regulation of renal nerve activity in cardiac failure. Am J Physiol 1995; 269:R1189-1196.
35. Huang C, Yoshimoto M, Miki K, Johns EJ. The contribution of brain angiotensin II to the baroreflex regulation of renal sympathetic nerve activity in conscious normotensive and hypertensive rats. J Physiol 2006; 574:597-604.
36. Kumada M, Terui N, Kuwaki T. Arterial baroreceptor reflex: its central and peripheral neural mechanisms. Prog Neurobiol 1990; 35:331-361.
37. Housley GD, Martin-Body RL, Dawson NJ, Sinclair JD. Brain stem projections of the glossopharyngeal nerve and its carotid sinus branch in the rat. Neuroscience 1987; 22:237-250.
38. Pickering AE, Simms AE, Paton JF. Dominant role of aortic baroreceptors in the cardiac baroreflex of the rat in situ. Auton Neurosci 2008; 142:32-39.
39. Sapru HN, Gonzalez E, Krieger AJ. Aortic nerve stimulation in the rat: cardiovascular and respiratory responses. Brain Res Bull 1981; 6:393-398.
40. Xing T, Pilowsky PM. Acute intermittent hypoxia in rat in vivo elicits a robust increase in tonic sympathetic nerve activity that is independent of respiratory drive. J Physiol 2010; 588:3075-3088.
41. Somers VK, Mark AL, Zavala DC, Abboud FM. Contrasting effects of hypoxia and hypercapnia on ventilation and sympathetic activity in humans. J Appl Physiol 1989; 67:2101-2106.
42. Rassaf T, Schueller P, Westenfeld R, Floege J, Eickholt C, Hennersdorf M, et al. Peripheral chemosensor function is blunted in moderate to severe chronic kidney disease. Int J Cardiol 2012; 155:201-205.
43. Li YL, Xia XH, Zheng H, Gao L, Li YF, Liu D, et al. Angiotensin II enhances carotid body chemoreflex control of sympathetic outflow in chronic heart failure rabbits. Cardiovasc Res 2006; 71:129-138.
44. Braga VA, Medeiros IA, Ribeiro TP, Franca-Silva MS, Botelho-Ono MS, Guimaraes DD. Angiotensin-II-induced reactive oxygen species along the SFO-PVN-RVLM pathway: implications in neurogenic hypertension. Braz J Med Biol Res 2011; 44:871-876.
45. Burton AR, Birznieks I, Bolton PS, Henderson LA,Macefield VG. Effects of deep and superficial experimentally induced acute pain on muscle sympathetic nerve activity in human subjects. J Physiol 2009; 587:183-193.
46. Sinoway LI, Li J. A perspective on the muscle reflex: implications for congestive heart failure. J Appl Physiol 2005; 99:5-22.
47. McMullan S, Pathmanandavel K, Pilowsky PM, Goodchild AK. Somatic nerve stimulation evokes qualitatively different somatosympathetic responses in the cervical and splanchnic sympathetic nerves in the rat. Brain Res 2008; 1217:139-147.
48. Krishnan AV, Phoon RK, Pussell BA, Charlesworth JA, Kiernan MC. Sensory nerve excitability and neuropathy in end stage kidney disease. J Neurol Neurosurg Psychiatry 2006; 77:548-551.
49. Phillips JK, Hopwood D, Loxley RA, Ghatora K, Coombes JD, Tan YS, et al. Temporal relationship between renal cyst development, hypertension and cardiac hypertrophy in a new rat model of autosomal recessive polycystic kidney disease. Kid Blood Press Res 2007; 30:129-144.
50. Ng K, Hildreth CM, Avolio AP, Phillips JK. Angiotensin-converting enzyme inhibitor limits pulse-wave velocity and aortic calcification in a rat model of cystic renal disease. Am J Physiol Renal Physiol 2011; 301:F959-F966.
51. Sanchez-Palacios M, Jones SY, DiBona GF. Role of angiotensin in renal sympathetic activation in nephrotic syndrome. Am J Physiol 1998; 274:R808-R813.
52. Paton JF, Sobotka PA, Fudim M, Engelman ZJ, Hart EC, McBryde FD, et al. The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases. Hypertension 2013; 61:5-13.